Estrella Immunopharma, Inc. (ESLA) stock
ESLANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as ESLAW
Financials through Q1 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.34+0.01 (+2.25%)
Close on Nov 19, 2026Market cap $14.81MP/E –Yield –
Estrella Immunopharma net income
Net income is the profit left for shareholders after every expense, interest and tax.
Estrella Immunopharma's net income for the twelve months ending Jun 30, 2024 was -$7.31M. For fiscal 2024 it was -$7.31M.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Jun 30, 2024 | -$7.31M | – |
| FY2021 | Dec 31, 2021 | -$247.72K | – |
Quarterly net income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026CQ3 2025 | Jun 30, 2026 | -$4.60M | – |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | -$3.95M | – |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | -$469.53K | – |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | -$1.02M | – |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | -$1.87M | – |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | -$135.80K | – |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | -$107.55K | – |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | -$3.56K | – |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | -$819 | – |
See a number that looks wrong?